Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after

• Published in: Quality of life research 2023-04, Vol.32 (4), p.989-1003
• Main Authors: Miret, Carme, Orive, Miren, Sala, Maria, García-Gutiérrez, Susana, Sarasqueta, Cristina, Legarreta, Maria Jose, Redondo, Maximino, Rivero, Amado, Castells, Xavier, Quintana, José M., Garin, Olatz, Ferrer, Montse
• Format: Article
• Language: English
• Subjects: Breast cancer; Breast Neoplasms; Chi-square test; Comorbidity; Female; Humans; Medical diagnosis; Medicine; Medicine & Public Health; Metastasis; Middle Aged; Prospective Studies; Public Health; Quality of Life - psychology; Quality of Life Research; Reference Values; Sociology; Surveys and Questionnaires
• ISSN: 0962-9343; 1573-2649
• DOI: 10.1007/s11136-022-03327-4

Purpose To obtain reference norms of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L, based on a population of Spanish non-metastatic breast cancer patients at diagnosis and 2 years after, according to relevant demographic and clinical characteristics. Methods Multicentric prospective cohort study including consecutive women aged ≥ 18 years with a diagnosis of incident non-metastatic breast cancer from April 2013 to May 2015. Health-related quality of life (HRQoL) questionnaires were administered between diagnosis and beginning the therapy, and 2 years after. HRQoL differences according to age, comorbidity and stage were tested with ANOVA or Chi Square test and multivariate linear regression models. Results 1276 patients were included, with a mean age of 58 years. Multivariate models of EORTC QLQ-C30 summary score and EQ-5D-5L index at diagnosis and at 2-year follow-up show the independent association of comorbidity and tumor stage with HRQoL. The standardized multivariate regression coefficient of EORTC QLQ-C30 summary score was lower (poorer HRQoL) for women with stage II and III than for those with stage 0 at diagnosis (− 0.11 and − 0.07, p